Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

JBSS vs BHST: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

JBSS Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 8–2 Matrix Metrics)

JBSS Overall Winner 6-Pillar Tally: JBSS 4 – 2 BHST Matrix Metrics: JBSS 8 – 2 BHST

As of Nov 20, 2026, John B. Sanfilippo & SON (JBSS) is the stronger overall head-to-head candidate over BioHarvest Sciences Inc. (BHST) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). JBSS carries a Unified Composite Score of 47.3/100 (HOLD) at $61.07 (10.1x Forward P/E, 6.7% operating margin), whereas BHST carries 58.2/100 (HOLD) at $1.30 (N/M Forward P/E, -18.0% operating margin).

  • Composite vs. Pillar Nuance: While BHST currently prints a higher short-term Unified Composite Score (58.2/100 HOLD vs. JBSS 47.3/100 HOLD), JBSS captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (6.7% vs. -18.0% operating margin) and revenue trajectory (-3.5% vs. +3.8% YoY).
  • Technical & Structure Timing Caution: JBSS is currently in a Breakdown options structure phase (RSI 50.6); meanwhile BHST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About JBSS vs BHST
JBSS NASDAQ Head-to-Head Winner
John B. Sanfilippo & SON
Sugar & Confectionery Products
$61.07
+0.49% 1D
Market Cap $710.6M
TTM Revenue $1.17B
Forward P/E 10.1x
Beta / 30D Vol 0.21β · 62% Vol
Unified Composite Score
47.3 / 100 HOLD
Tech 53.0 Fund 55.0 Flow 62.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 51
RSI-14: 50.6 · SMA20: $58.58 · SMA50: $63.81
BHST NASDAQ
BioHarvest Sciences Inc. Common Stock
Pharmaceutical Preparations
$1.30
-1.52% 1D
Market Cap $29.9M
TTM Revenue $35M
Forward P/E N/M
Beta / 30D Vol 0.25β · 86% Vol
Unified Composite Score
58.2 / 100 HOLD
Tech 75.0 Fund 57.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.1%), weak momentum, RSI 37
RSI-14: 37.2 · SMA20: $1.55 · SMA50: $1.58

6-Pillar Scorecard Institutional Category Breakdown (JBSS 4 – 2 BHST)

Columns: Metric · JBSS · BHST
1. Valuation Multiples JBSS
Forward P/E 10.1x N/M
Trailing P/E 12.7x N/M
PEG Ratio 1.52x N/M
EV / Revenue 0.7x 0.7x
2. Growth & Scale BHST
Revenue Growth (YoY) -3.5% +3.8%
Earnings Growth (YoY) -30.2% +0.0%
TTM Revenue (USD) $1.17B $35M
Market Cap $710.6M $29.9M
3. Profitability & Quality JBSS
Gross Margin 17.7% 59.0%
Operating Margin 6.7% -18.0%
Net Profit Margin 4.8% -31.2%
Return on Equity (ROE) 15.4% -142.5%
4. Balance Sheet & Cash Flow JBSS
Cash Generation (TTM) $30M -$9.4M
Cash Flow Margin 2.6% -26.6%
Net Cash / Leverage $140M Net Debt (0.38x D/E) $5.1M Net Cash
Dividend Yield 1.55% None (0.00%)
5. Options & Positioning JBSS
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 92.9% (18th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat BHST
OpEx & R&D Intensity 11.0% of Rev ($128M) 77.0% of Rev ($27M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Packaged Foods Operator Packaged Foods Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: JBSS (8) vs BHST (2)
Institutional Metric JBSS BHST Criterion Row Edge
Market Capitalization
Scale
$710.6M $29.9M Larger Scale JBSS
Trailing P/E Ratio
Valuation
12.7x N/M Lower Multiple JBSS
Forward P/E Ratio
Valuation
10.1x N/M Lower Multiple JBSS
Revenue Growth (YoY)
Growth
-3.5% +3.8% Higher Growth BHST
Operating Margin (TTM)
Profitability
6.7% -18.0% Higher Margin JBSS
Net Profit Margin
Profitability
4.8% -31.2% Higher Margin JBSS
Return on Equity (ROE)
Capital Efficiency
15.4% -142.5% Higher ROE JBSS
52-Week Range Position
Momentum
25% ($51–$92) 6% ($1–$7) Stronger Trend JBSS
Beta / 30D Volatility
Risk Regime
0.21β · 62% Vol 0.25β · 86% Vol Lower Realized Risk JBSS
Unified Institutional Score
Composite Signal
47.3 / 100 (HOLD) 58.2 / 100 (HOLD) Higher Composite BHST
Trailing 12M Revenue (USD)
Operating Scale
$1.17B $35M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
17.7% 59.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.52x PEG · 0.7x EV/Rev N/M PEG · 0.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$30M ($140M Net Debt (0.38x D/E)) -$9.4M ($5.1M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon JBSS +12.07 pp
JBSS: -10.55% · BHST: -22.62%
3M Horizon JBSS +17.49 pp
JBSS: -19.1% · BHST: -36.59%
6M Horizon JBSS +45.93 pp
JBSS: -20.39% · BHST: -66.32%
1Y Horizon JBSS +68.04 pp
JBSS: -11.36% · BHST: -79.4%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period JBSS Revenue BHST Revenue JBSS Op. Margin BHST Op. Margin Margin Leader
FY2019 $880M N/A 6.7% N/A JBSS
FY2020 $880M N/A 8.9% N/A JBSS
FY2021 $860M N/A 9.9% N/A JBSS
FY2022 $960M N/A 9.1% N/A JBSS
FY2023 $1.00B $10M 9.0% -78.6% JBSS
FY2024 $1.07B $30M 8.0% -27.7% JBSS
FY2025 $1.11B $30M 7.7% -16.2% JBSS
FY2026 $1.18B N/A 7.6% N/A JBSS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
JBSS BREAKDOWN
99d in phase · OBV ACCUMULATION
Current IV 92.9%
IV Percentile 18th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact JBSS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BHST UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BHST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
JBSS Moat Profile Cyclical / Execution-Driven Positioning
Packaged Foods Operator
Competes within the Packaged Foods value chain with $710.6M market capitalization and 6.7% operating margin.
OpEx & R&D Reinvestment 11.0% of Rev ($128M)
90D Engineering Disclosures 0 Published
BHST Moat Profile Cyclical / Execution-Driven Positioning
Packaged Foods Operator
Competes within the Packaged Foods value chain with $29.9M market capitalization and -18.0% operating margin.
OpEx & R&D Reinvestment 77.0% of Rev ($27M)
90D Engineering Disclosures 0 Published

Investor FAQ JBSS vs BHST Key Questions & Quantitative Answers

As of Nov 20, 2026, John B. Sanfilippo & SON (JBSS) is the stronger overall head-to-head candidate over BioHarvest Sciences Inc. (BHST) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). JBSS carries a Unified Composite Score of 47.3/100 (HOLD) at $61.07 (10.1x Forward P/E, 6.7% operating margin), whereas BHST carries 58.2/100 (HOLD) at $1.30 (N/M Forward P/E, -18.0% operating margin). Composite vs. Pillar Nuance: While BHST currently prints a higher short-term Unified Composite Score (58.2/100 HOLD vs. JBSS 47.3/100 HOLD), JBSS captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (6.7% vs. -18.0% operating margin) and revenue trajectory (-3.5% vs. +3.8% YoY). Technical & Structure Timing Caution: JBSS is currently in a Breakdown options structure phase (RSI 50.6); meanwhile BHST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BHST leads the Growth & Scale pillar: JBSS posts -3.5% YoY revenue growth and -30.2% YoY earnings growth on $1.17B TTM revenue (17.7% gross margin, 6.7% operating margin), compared with BHST at +3.8% YoY revenue growth and +0.0% YoY earnings growth on $35M TTM revenue (59.0% gross margin, -18.0% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), JBSS cumulative revenue shifted +34.1% while BHST shifted +200.0%. In operating R&D and SG&A reinvestment, JBSS deploys 11.0% of Rev ($128M) (0 90-day corporate R&D disclosures) versus 77.0% of Rev ($27M) (0 disclosures) for BHST.

JBSS screens cheaper on headline valuation multiples. JBSS trades at 10.1x Forward P/E, 12.7x Trailing P/E, 1.52x PEG, and 0.7x EV/Revenue (2.6% FCF margin), whereas BHST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.7x EV/Revenue (-26.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against JBSS (15.4% ROE) versus BHST (-142.5% ROE) capital efficiency.

In options market volatility and institutional positioning, JBSS carries 92.9% implied volatility (18th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.21β · 62% Vol realized risk). By comparison, BHST carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.25β · 86% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.